pyrazines has been researched along with carboplatin in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (56.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bold, RJ; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Reddy, KG | 1 |
| Aghajanian, C | 1 |
| Edelman, MJ | 1 |
| Aghajanian, C; Dizon, DS; Dupont, J; Raizer, JJ; Sabbatini, P; Spriggs, DR | 1 |
| Soria, JC | 1 |
| Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ | 1 |
| Coleman, RL; Gershenson, DM; Johnston, TA; Landen, CN; Levenback, C; Milam, MR; Ramirez, PT | 1 |
| Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S | 1 |
| Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, NR; Hauge, MD; Jaslowski, AJ; Jatoi, A; Ma, C; Moore, DF; Rowland, KM; Stella, PJ; Thomas, SP | 1 |
| Chow, L; Eckhardt, SG; Gore, L; Lieu, C; Morrow, M; O'Bryant, CL; Pierson, AS; Tran, ZV; Wright, JJ | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Armstrong, MB; Castle, VP; Mody, R; Opipari, AW; Schumacher, KR; Yanik, GA | 1 |
| Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ | 1 |
| Bedor, M; Burrows, W; Edelman, MJ; Krasna, MJ; Smith, R; Suntharalingam, M | 1 |
| Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ | 1 |
| Anderlini, P; Fanale, M; Fayad, L; Horowitz, S; Ji, Y; Kwak, LW; Liboon, MJ; Nunez, C; Popat, U; Pro, B; Samaniego, F; Younes, A | 1 |
| Bathini, V; Bradley, K; Hanrahan-Boshes, M; Hutchinson, L; Perez-Soler, R; Piperdi, B; Walsh, WV; Zhou, Z | 1 |
| Fujii, T; Hiraike, H; Kawana, K; Kozuma, S; Miyamoto, Y; Nagasaka, K; Nakagawa, K; Nakagawa, S; Oda, K; Seiki, T; Sone, K; Taketani, Y; Tanikawa, M; Wada-Hiraike, O; Yano, T | 1 |
| Eatock, MM; Gallagher, R; James, CR; Law, D; Millar, J; Morris, M; Napier, E; Purcell, C; Turkington, RC; Wilson, RH | 1 |
| Dobra, K; Hjerpe, A; Mundt, F; Nilsonne, G; Souri, P; Szulkin, A; Wasik, AM | 1 |
| Adjei, AA; Aubry, MC; Bearden, JD; Foster, NR; Johnson, DB; Mandrekar, SJ; Mattar, BI; Meyers, JP; Molina, JR; Northfelt, DW; Rowland, KM; Schild, SE; Thomas, SP; Zhao, Y | 1 |
| Berkowitz, RS; Bonventre, JV; Crum, CP; D'Andrea, AD; Decker, B; Do, KT; Feltmate, CM; Hill, SJ; Horowitz, NS; Kochupurakkal, BS; Konstantinopoulos, PA; Liu, JF; Matulonis, UA; Morizane, R; Muto, MG; Nguyen, H; Nucci, MR; Roberts, EA; Shapiro, GI; Swisher, EM; Worley, MJ; Yang, C | 1 |
| Amant, F; Annibali, D; Baietti, MF; Floris, G; Impens, F; Marangoni, E; Marinelli, O; Moens, S; Neven, P; Sablina, AA; Van Haver, D; Zhao, P | 1 |
| Castellano, GM; Garbuzenko, OB; Malhotra, J; Minko, T; Pine, SR; Sabaawy, HE; Zeeshan, S | 1 |
1 review(s) available for pyrazines and carboplatin
| Article | Year |
|---|---|
Clinical update: novel targets in gynecologic malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cisplatin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; NF-kappaB-Inducing Kinase; Ovarian Neoplasms; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines | 2004 |
13 trial(s) available for pyrazines and carboplatin
| Article | Year |
|---|---|
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrazines | 2005 |
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2007 |
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Proteasome Inhibitors; Pyrazines | 2008 |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome | 2008 |
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cardia; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Pyrazines; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2008 |
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Thrombocytopenia | 2009 |
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2009 |
Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Early Termination of Clinical Trials; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Protease Inhibitors; Pyrazines; Radiotherapy; Respiratory Insufficiency | 2010 |
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms | 2010 |
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Pyrazines; Recurrence; Treatment Outcome; Young Adult | 2011 |
Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrazines; Survival Rate; Treatment Outcome; United States; Vascular Endothelial Growth Factor A | 2012 |
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Deoxycytidine; Epirubicin; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Proteasome Inhibitors; Pyrazines | 2014 |
A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pyrazines; Survival Analysis | 2015 |
11 other study(ies) available for pyrazines and carboplatin
| Article | Year |
|---|---|
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2004 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Research; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2006 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
Bortezomib as a therapeutic candidate for neuroblastoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Genes, p53; Humans; Irinotecan; Neuroblastoma; NF-kappa B; Pyrazines | 2008 |
Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carboplatin; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Membrane Proteins; Mice; Mice, Inbred ICR; Mice, SCID; Paclitaxel; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Uterine Cervical Neoplasms | 2013 |
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Multidrug Resistance-Associated Proteins; Pemetrexed; Pyrazines; Selenious Acid | 2013 |
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Deoxycytidine; DNA Repair; DNA Replication; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Culture Techniques; Organoids; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles | 2018 |
The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Protein-Tyrosine Kinases; Proteome; Pyrazines; Pyrazoles; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
Topics: Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; DNA; Humans; Lung; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; TOR Serine-Threonine Kinases; Triazoles | 2022 |